krestin (PSK)

01/01/1992 - "PSK was most effective when administered at 100 mg/kg every other day ten times starting from the day after tumor inoculation. "
08/01/1998 - "These results strongly suggest that AGE is as effective as PSK, and could serve as a potent biological response modifier on NK cells and T lymphocytes, and subsequently inhibit the growth of transplanted tumors."
03/01/1998 - "Although pulmonary macrophages (PAMs), lymphocyte and eosinophil in bronchoalveolar lavage (BAL) fluid increased following tumor cell inoculation, in addition to these findings we found that PSK caused an increase in BAL neutrophil levels causing increased of target cell toxicity and a marked decrease in the size and the number of lung metastatic foci. "
08/01/1988 - "Immunized spleen cells were taken from mice which had been cured by the intratumoral administration of 5 mg of PSK and were injected into the Meth-A tumor on day 3. Adoptive transfer of PSK immunized spleen cells caused the complete regression of Meth-A tumors. "
02/01/1986 - "The conditions necessary for long-term survival with PS-K were thought to be as follows: that the tumor almost disappears as a result of irradiation and that the condition of the host is superior to that of the tumor in the tumor-host relationship. "

01/01/1992 - "From these results, 580 micrograms/ml is postulated to be the most appropriate threshold value for predicting the prognosis of advanced gastric cancer patients, and it is suggested that PSK would be most effective in patients whose preoperative IAP level is lower than the threshold level."
11/01/2012 - "This combination of immunochemotherapy using S-1/PTX/PSK can be safe and effective, and is an initial treatment option for unresectable advanced gastric cancer."
06/01/2015 - "The aim of the present study was to evaluate the clinical significance of protein-bound polysaccharide K (PSK) in patients with primary gastric cancer who were being treated with an oral fluoropyrimidine (S-1). "
02/01/2015 - "Therefore, our study indicates that PSK has potential utility as an anti-fibrotic agent in the treatment of gastric cancer patients with PC."
08/01/2012 - "The aim of this study was to evaluate the effect of PSK on the overall survival of patients with gastric cancer. "

01/01/1990 - "Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer."
02/01/1992 - "These results indicate that adjuvant immunochemotherapy with PSK was beneficial for curatively resected colorectal cancer."
06/01/1989 - "From these results, adjuvant immunochemotherapy with PSK was considered beneficial for curatively resected colorectal cancer."
02/01/2009 - "The present retrospective study suggests a possible efficacy of postoperative adjuvant therapy with UFT plus PSK in elderly patients over 70 years of age with resected colorectal cancer."
12/01/2013 - "This study suggests that a low preoperative Lym is a good predictor for response to PSK in patients with Stage II or III colorectal cancer."

10/01/1994 - "These results suggest that PSK may be effective for the suppression of liver metastasis through activation of liver-associated NK cells."
08/01/2012 - "In patients with pN3 lymph node metastasis, median overall survival was better in the PSK group compared with the control group (p=0.032). "
03/01/2012 - "The suppression of angiogenesis by PSK may be one of the mechanisms of the inhibition of hepatic metastasis."
03/01/2012 - "PSK may suppress metastasis induced by hepatic I/R. "
03/01/2012 - "PSK administration significantly (p < 0.05) suppressed the I/R-induced increase in hepatic metastasis of RCN-H4 cells. "

10/29/1987 - "A biological response modifier, PSK, inhibits human immunodeficiency virus infection in vitro."
11/01/1984 - "This resistance to the infection could be transferred with peritoneal exudate cells (PEC) but not with non-adherent PE cells of PSK-treated mice. "
01/01/1984 - "This resistance to the infection could be transferred with adherent peritoneal exudate cells (PEC) but not with nonadherent or adherent spleen cells of PSK-treated mice. "
12/01/1979 - "The protective activities of KS-2 against influenza virus infection in mice are discussed in view of the immunopotentiation of the host animals."
12/01/1979 - "Both PO and IP administrations of KS-2 protected mice against infection and significant antiviral activities were achieved not only by prophylactic but also chemotherapeutic administration. "